Opinion|Videos|August 8, 2024
Esketamine Safety Mechanisms and Bioavailability
Geoffrey Grammer, MD closes this series highlighting the administration options of esketamine, its safety profile, and the importance of monitoring patients using this treatment.
Advertisement
Advertisement
Related to this article
Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study in > 1000 participants with highly chronic TRD.
Advertisement
Advertisement
Trending on HCPLive
1
Lp(a)HORIZON, Oral PCSK9s, and 2027 Lipid Trials, with Kausik Ray, MD, MBChB, MPhil
2
Single Dose of CIDEB siRNA Normalizes Liver Fat in MASLD Through 36 Weeks
3
ESSENCE: Semaglutide Improves Liver Markers in MASH Without Obesity
4
Elebsiran Plus Tobevibart Suppresses HDV RNA in Phase 3 ECLIPSE 1 Trial
5